Enliven Therapeutics, Inc. Common Stock (ELVN)
Enliven Therapeutics, Inc. (ELVN) is a biotechnology company focused on developing targeted small molecule medicines for cancer and genetic diseases. The firm specializes in utilizing precision medicine approaches to create therapies that modulate disease-related pathways, aiming to improve treatment outcomes and reduce side effects.
Company News
Clinical-stage biotech Enliven Therapeutics reported Q2 2025 results, highlighting positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia and a strengthened cash position of $490.5 million following a $230 million public offering.
Enliven Therapeutics (ELVN) is a good choice for trend investors due to its recent price increase, positive earnings estimate revisions, and strong fundamentals, making it a Zacks Rank #2 (Buy) stock.
Enliven Therapeutics reported positive data from a Phase 1 trial of its drug ELVN-001for chronic myeloid leukemia, with a 44% major molecular response rate by 24 weeks and a favorable safety profile.
Anish Patel, the Chief Operating Officer of Enliven Therapeutics, has sold over $1.25 million worth of company stock in a series of transactions. The sales were conducted under a Rule 10b5-1 trading plan, and Patel remains a significant shareholder in the company.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Disc Medicine (IRON), Westamerica (WABC) and Enliven (ELVN).